Latest Monoclonal antibodies Stories
SAN DIEGO, Feb. 2, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc.
SALT LAKE CITY, Jan.
-33% rate of DAS28-CRP remission or low disease activity reported in Phase 2a cohort- MONROVIA, Calif., Jan. 29, 2015 /PRNewswire/ -- Xencor, Inc.
- 90% of subjects had reduction of free IgE to below the limit of detection by the end of XmAb7195 infusion, including at lowest dose evaluated of 0.3 mg/kg - MONROVIA, Calif.,
SAN DIEGO, Jan. 28, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc.
PLANTATION, Fla., Jan.
TARRYTOWN, N.Y. and PARIS, Jan. 26, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S.
LONDON, January 22, 2015 /PRNewswire/ -- Report Details Treating Crohn's disease and ulcerative colitis - how to find R&D trends, opportunities and revenue
Researchmoz.us announces new research report on Antibody Partnering Terms and Agreements to it's huge collection.
- A person in a secondary role, specifically the second most important character (after the protagonist).
More Images (1 images) »